Author

Chris McCann

Queen's University Belfast

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

Connor N. BrowniD· 2 shared Deborah Y. Moss· 2 shared Emma M. KerriD· 2 shared Matilda Downs· 2 shared Nikita LewisiD· 2 shared Sarah Maguire· 2 shared Vicky M. CoyleiD· 2 shared William J. McDaidiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Connor N. BrownORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer

Deborah Y. Moss, Connor N. Brown, Andrew M. Shaw, Chris McCann, Nikita Lewis, Matilda Downs, Rebecca Wurelly, Ciara Cunningham, Aaron Philips, Niamh Doherty, Sarah Gallagher, William J. McDaid, Andrew J. Roe, Aisling Y. Coughlan, Brenton Cavanagh, , Emma M. Kerr

This study identifies mitochondrial metabolism as a key factor in 5-fluorouracil resistance in colorectal cancer and shows that targeting mitochondrial Complex I can enhance chemotherapy effectiveness.

Nature Metabolism · Jul 23, 2026Peer-reviewedCancer Biology

Mutant KRAS dosage contributes to heterogeneity in lung cancer therapeutic response

Alice T. Browne, Chris McCann, William J. McDaid, Nikita Lewis, Sandhya Sridhar, Gary Joseph Doherty, Deborah Y. Moss, Matilda Downs, Stephen Marry, A.R. Phillips, Connor N. Brown, Alyson Speed, Gemma E. Logan, Gera L. Jellema, James R. Bradford, , Emma M. Kerr

This study shows that mutant KRAS dosage affects therapeutic response in lung cancer, with higher dosages linked to resistance to platinum therapy and sensitivity to pS6K inhibition.

bioRxiv · May 9, 2026 · PreprintCancer Biology